Efficacy and safety of tacrolimus versus mycophenolate mofetil as induction treatment and low-dose tacrolimus as treatment for lupus nephritis: a meta-analysis

[1]  Y. Lee,et al.  Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials , 2022, Lupus.

[2]  Chang-Keun Lee,et al.  Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea , 2022, Journal of rheumatic diseases.

[3]  J. Sung,et al.  Safety of Tacrolimus in Autoimmune Disease: Results From Post-marketing Surveillance in South Korea , 2021, Journal of Rheumatic Diseases.

[4]  S. Bang,et al.  Clinical and Genetic Risk Factors Associated With the Presence of Lupus Nephritis , 2021, Journal of rheumatic diseases.

[5]  Y. Lee,et al.  Association Between Signal Transducers and Activators of Transcription 4 rs7574865 Polymorphism and Systemic Lupus Erythematosus: A Meta-analysis , 2020 .

[6]  Y. Lee,et al.  Circulating Interleukin-37 Levels in Rheumatoid Arthritis and Systemic Lupus Erythematosus and Their Correlations With Disease Activity: A Meta-analysis , 2020, Journal of Rheumatic Diseases.

[7]  C. Mok,et al.  Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis , 2020, Annals of the Rheumatic Diseases.

[8]  Y. Lee,et al.  Circulating Interleukin-18 Level in Systemic Lupus Erythematosus , 2020 .

[9]  Young Lee.  Strengths and Limitations of Meta-Analysis , 2019, The Korean Journal of Medicine.

[10]  S. Rattanasiri,et al.  Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial , 2018, Lupus.

[11]  Y. Lee.  An overview of meta-analysis for clinicians , 2017, The Korean journal of internal medicine.

[12]  M. Ward,et al.  Risk of End‐Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Meta‐Analysis , 2016, Arthritis & rheumatology.

[13]  Y. H. Lee,et al.  Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis , 2016, Lupus.

[14]  C. Mok,et al.  Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up , 2014, Annals of the rheumatic diseases.

[15]  D. D'cruz,et al.  Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. , 2016, Autoimmunity reviews.

[16]  E. Ito,et al.  Long-Term Tacrolimus-Based Immunosuppressive Treatment for Young Patients with Lupus Nephritis: A Prospective Study in Daily Clinical Practice , 2013, Nephron Clinical Practice.

[17]  N. Chen,et al.  Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome , 2012, Nephrology.

[18]  N. Chen,et al.  Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  H. Hashimoto,et al.  Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study , 2009, Modern rheumatology.

[20]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[21]  Z. Morad,et al.  Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis , 2005, Nephrology.

[22]  M. Petri,et al.  Cyclophosphamide: new approaches for systemic lupus erythematosus , 2004, Lupus.

[23]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[24]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[25]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[26]  M. Okuhara,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987, The Journal of antibiotics.